Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
- 1 March 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 18 (3), 296-307
- https://doi.org/10.1016/s1473-3099(17)30751-x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Hypersensitivity Reactions Associated With Fidaxomicin UseClinical Infectious Diseases, 2013
- Fidaxomicin for Clostridium difficile-Associated DiarrhoeaClinical Drug Investigation, 2012
- Fidaxomicin for Clostridium difficile-Associated DiarrhoeaClinical Drug Investigation, 2012
- Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile InfectionClinical Infectious Diseases, 2012
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDIClinical Infectious Diseases, 2012
- Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistanceTrends in Microbiology, 2012
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2012
- Consequences of Clostridium difficile infection: understanding the healthcare burdenClinical Microbiology & Infection, 2012
- Fidaxomicin versus Vancomycin forClostridium difficileInfectionNew England Journal of Medicine, 2011
- A review of mortality due to Clostridium difficile infectionJournal of Infection, 2010